Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $173
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek maintains an Overweight rating on Ascendis Pharma (ASND) and raises the price target from $152 to $173.
February 06, 2024 | 2:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Li Watsek reaffirmed an Overweight rating on Ascendis Pharma and increased the price target from $152 to $173.
The upgrade in the price target by a reputable analyst like Li Watsek suggests a strong confidence in Ascendis Pharma's future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in ASND's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100